Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma

Endocrine-Related Cancer

Volumn 16, Issue 4, 2009, Pages 1283-1289

  Hänscheid, Heribert ^a   Lassmann, Michael ^a   Luster, Markus ^a   Kloos, Richard T ^b   Reiners, Christoph ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIATED THYROID CARCINOMA; DOSIMETRY; HUMAN; METASTASIS; RADIATION DOSE; RADIATION EXPOSURE; RADIOFREQUENCY ABLATION; THYROID CARCINOMA; WHOLE BODY COUNTING;

ADOLESCENT; ADULT; AGED; ALGORITHMS; CELL DIFFERENTIATION; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROGNOSIS; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RELATIVE BIOLOGICAL EFFECTIVENESS; THYROID NEOPLASMS; TISSUE DISTRIBUTION; WHOLE-BODY COUNTING; YOUNG ADULT;

EID: 70349137404     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0076     Document Type: Article

References (14)

1. Benua RS & Leeper RD 1986 A method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of I-131. In Frontiers in Thyroidology, vol 2, pp 1317-1321. Eds G Meideiros-Neto & E Gaitan. New York: Plenum.
2. Benua RS, Cicale NR, Sonenberg M & Rawson RW 1962 Relation of radioiodine dosimetry to results and complications in treatment of metastatic thyroid cancer. American Journal of Roentgenology 87 171-182.
3. Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG & Gulec SA 2003 Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. Journal of Nuclear Medicine 44 451-456. (Pubitemid 39586024)
4. Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson P, Wahl R, Schlumberger M, Ricard M et al. 2006 Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. Journal of Nuclear Medicine 47 648-654.
5. 124I PET and 3-dimensional internal dosimetry software. Journal of Nuclear Medicine 48 143-149.
6. 131I diagnostic activities on the biokinetics of thyroid remnants. Journal of Nuclear Medicine 4 619-625.
7. Lassmann M, Hänscheid H, Chiesa C, Hindorf C, Flux G & Luster M 2008 EANM dosimetry committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. European Journal of Nuclear Medicine and Molecular Imaging 35 1405-1412.
8. Retzlaff JA, Tauxe WN, Kiely JM & Stroebel CF 1969 Erythrocyte volume, plasma volume, and lean body mass in adult men and women. Blood 33 649-667.
9. Sgouros G 2005 Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer. Journal of Nuclear Medicine 46 899-900. (Pubitemid 43750773)
10. 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. Journal of Nuclear Medicine 45 1366-1372.
11. Sisson JC, Shulkin BL & Lawson S 2003 Increasing efficacy and safety of treatments of patients with well-differentiated thyroid carcinoma by measuring body retentions of 131I. Journal of Nuclear Medicine 44 898-903. (Pubitemid 39663400)
12. Thomas SR, Samaratunga RC, Sperling M & Maxon HR III 1993 Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer. Nuclear Medicine and Biology 20 157-162. (Pubitemid 23043069)
13. 131I kinetics in blood. Radiation Protection Dosimetry 109 249-252.
14. Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K & Larson SM 2006 Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. Journal of Nuclear Medicine 47 1587-1591. (Pubitemid 47545022)